APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Equine Rhinopneumonitis Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Equine Rhinopneumonitis Vaccine Market Outlook and Growth Opportunities 2026

Report ID 17398916042 January 2026197 pages

Choose your research edition.

Industry ResearchEquine Rhinopneumonitis Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Equine Rhinopneumonitis Vaccine Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Equine Rhinopneumonitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Equine Rhinopneumonitis Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Equine Rhinopneumonitis Vaccine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Equine Rhinopneumonitis Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Equine Rhinopneumonitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Equine Rhinopneumonitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Equine Rhinopneumonitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Equine Rhinopneumonitis Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Equine Rhinopneumonitis Vaccine market include Merck, Zoetis, Santa Cruz Animal Health, Nisseiken Co., Ltd. and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Equine Rhinopneumonitis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Equine Rhinopneumonitis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Equine Rhinopneumonitis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Equine Rhinopneumonitis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Equine Rhinopneumonitis Vaccine Segment by Company

Merck

Zoetis

Santa Cruz Animal Health

Nisseiken Co., Ltd.

Boehringer Ingelheim

Equine Rhinopneumonitis Vaccine Segment by Type

Live

Inactivated

Equine Rhinopneumonitis Vaccine Segment by Application

Veterinary Pharmacy

Online Sale

Others

Equine Rhinopneumonitis Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Equine Rhinopneumonitis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Equine Rhinopneumonitis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Equine Rhinopneumonitis Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Equine Rhinopneumonitis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Equine Rhinopneumonitis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Equine Rhinopneumonitis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Equine Rhinopneumonitis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Equine Rhinopneumonitis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Equine Rhinopneumonitis Vaccine industry.

Chapter 3: Detailed analysis of Equine Rhinopneumonitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Equine Rhinopneumonitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Equine Rhinopneumonitis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Equine Rhinopneumonitis Vaccine Industry Trends Table 2. Equine Rhinopneumonitis Vaccine Industry Drivers Table 3. Equine Rhinopneumonitis Vaccine Industry Opportunities and Challenges Table 4. Equine Rhinopneumonitis Vaccine Industry Restraints Table 5. Global Equine Rhinopneumonitis Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Equine Rhinopneumonitis Vaccine Revenue Share by Company (2021-2026) Table 7. Global Equine Rhinopneumonitis Vaccine Sales Volume by Company (Units) & (2021-2026) Table 8. Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Equine Rhinopneumonitis Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Equine Rhinopneumonitis Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Equine Rhinopneumonitis Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Equine Rhinopneumonitis Vaccine Company, Product Type & Application Table 13. Global Equine Rhinopneumonitis Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Equine Rhinopneumonitis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Live Table 18. Significant Companies of Inactivated Table 19. Global Equine Rhinopneumonitis Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global Equine Rhinopneumonitis Vaccine Sales Volume by Type (2021-2026) & (Units) Table 21. Global Equine Rhinopneumonitis Vaccine Sales Volume by Type (2027-2032) & (Units) Table 22. Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Equine Rhinopneumonitis Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Equine Rhinopneumonitis Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Equine Rhinopneumonitis Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Veterinary Pharmacy Table 30. Significant Companies of Online Sale Table 31. Significant Companies of Others Table 32. Global Equine Rhinopneumonitis Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 33. Global Equine Rhinopneumonitis Vaccine Sales Volume by Application (2021-2026) & (Units) Table 34. Global Equine Rhinopneumonitis Vaccine Sales Volume by Application (2027-2032) & (Units) Table 35. Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Equine Rhinopneumonitis Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Equine Rhinopneumonitis Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Equine Rhinopneumonitis Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Equine Rhinopneumonitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 43. Global Equine Rhinopneumonitis Vaccine Sales by Region (2021-2026) & (Units) Table 44. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Equine Rhinopneumonitis Vaccine Sales by Region (2027-2032) & (Units) Table 46. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Equine Rhinopneumonitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Equine Rhinopneumonitis Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Equine Rhinopneumonitis Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Equine Rhinopneumonitis Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Equine Rhinopneumonitis Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Equine Rhinopneumonitis Vaccine Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Global Equine Rhinopneumonitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Equine Rhinopneumonitis Vaccine Sales by Country (2021-2026) & (Units) Table 57. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Equine Rhinopneumonitis Vaccine Sales by Country (2027-2032) & (Units) Table 59. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Equine Rhinopneumonitis Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Equine Rhinopneumonitis Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Equine Rhinopneumonitis Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Equine Rhinopneumonitis Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Equine Rhinopneumonitis Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Merck Equine Rhinopneumonitis Vaccine Product Portfolio Table 68. Merck Recent Development Table 69. Zoetis Company Information Table 70. Zoetis Business Overview Table 71. Zoetis Equine Rhinopneumonitis Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Zoetis Equine Rhinopneumonitis Vaccine Product Portfolio Table 73. Zoetis Recent Development Table 74. Santa Cruz Animal Health Company Information Table 75. Santa Cruz Animal Health Business Overview Table 76. Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Product Portfolio Table 78. Santa Cruz Animal Health Recent Development Table 79. Nisseiken Co., Ltd. Company Information Table 80. Nisseiken Co., Ltd. Business Overview Table 81. Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Product Portfolio Table 83. Nisseiken Co., Ltd. Recent Development Table 84. Boehringer Ingelheim Company Information Table 85. Boehringer Ingelheim Business Overview Table 86. Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Product Portfolio Table 88. Boehringer Ingelheim Recent Development Table 89. Key Raw Materials Table 90. Raw Materials Key Suppliers Table 91. Equine Rhinopneumonitis Vaccine Distributors List Table 92. Equine Rhinopneumonitis Vaccine Customers List Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Equine Rhinopneumonitis Vaccine Product Image Figure 2. Global Equine Rhinopneumonitis Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Equine Rhinopneumonitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Equine Rhinopneumonitis Vaccine Sales (2021-2032) & (Units) Figure 5. Global Equine Rhinopneumonitis Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Equine Rhinopneumonitis Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Live Image Figure 10. Inactivated Image Figure 11. Global Equine Rhinopneumonitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global Equine Rhinopneumonitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Equine Rhinopneumonitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Equine Rhinopneumonitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Type (2021-2032) Figure 17. Veterinary Pharmacy Image Figure 18. Online Sale Image Figure 19. Others Image Figure 20. Global Equine Rhinopneumonitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 21. Global Equine Rhinopneumonitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Equine Rhinopneumonitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Equine Rhinopneumonitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Equine Rhinopneumonitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 27. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Equine Rhinopneumonitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Equine Rhinopneumonitis Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Equine Rhinopneumonitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Equine Rhinopneumonitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Equine Rhinopneumonitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Equine Rhinopneumonitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Equine Rhinopneumonitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Equine Rhinopneumonitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Equine Rhinopneumonitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Equine Rhinopneumonitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Equine Rhinopneumonitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Equine Rhinopneumonitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Equine Rhinopneumonitis Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Equine Rhinopneumonitis Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Live
  • Inactivated
Applications
  • Veterinary Pharmacy
  • Online Sale
  • Others
Companies covered
  • Merck
  • Zoetis
  • Santa Cruz Animal Health
  • Nisseiken Co., Ltd.
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Equine Rhinopneumonitis Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Equine Rhinopneumonitis Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Equine Rhinopneumonitis Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Equine Rhinopneumonitis Vaccine Market Dynamics
  1. 2.1 Equine Rhinopneumonitis Vaccine Industry Trends
  2. 2.2 Equine Rhinopneumonitis Vaccine Industry Drivers
  3. 2.3 Equine Rhinopneumonitis Vaccine Industry Opportunities and Challenges
  4. 2.4 Equine Rhinopneumonitis Vaccine Industry Restraints
3 Equine Rhinopneumonitis Vaccine Market by Company
  1. 3.1 Global Equine Rhinopneumonitis Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Equine Rhinopneumonitis Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Equine Rhinopneumonitis Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Equine Rhinopneumonitis Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Equine Rhinopneumonitis Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Equine Rhinopneumonitis Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Equine Rhinopneumonitis Vaccine Company Product Type and Application
  8. 3.8 Global Equine Rhinopneumonitis Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Equine Rhinopneumonitis Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Equine Rhinopneumonitis Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Equine Rhinopneumonitis Vaccine Market by Type
  1. 4.1 Equine Rhinopneumonitis Vaccine Type Introduction
  2. 4.1.1 Live
  3. 4.1.2 Inactivated
  4. 4.2 Global Equine Rhinopneumonitis Vaccine Sales Volume by Type
  5. 4.2.1 Global Equine Rhinopneumonitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Equine Rhinopneumonitis Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Equine Rhinopneumonitis Vaccine Sales Value by Type
  9. 4.3.1 Global Equine Rhinopneumonitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Equine Rhinopneumonitis Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Equine Rhinopneumonitis Vaccine Sales Value Share by Type (2021-2032)
5 Equine Rhinopneumonitis Vaccine Market by Application
  1. 5.1 Equine Rhinopneumonitis Vaccine Application Introduction
  2. 5.1.1 Veterinary Pharmacy
  3. 5.1.2 Online Sale
  4. 5.1.3 Others
  5. 5.2 Global Equine Rhinopneumonitis Vaccine Sales Volume by Application
  6. 5.2.1 Global Equine Rhinopneumonitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Equine Rhinopneumonitis Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Equine Rhinopneumonitis Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Equine Rhinopneumonitis Vaccine Sales Value by Application
  10. 5.3.1 Global Equine Rhinopneumonitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Equine Rhinopneumonitis Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Equine Rhinopneumonitis Vaccine Sales Value Share by Application (2021-2032)
6 Equine Rhinopneumonitis Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Equine Rhinopneumonitis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Equine Rhinopneumonitis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Equine Rhinopneumonitis Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Equine Rhinopneumonitis Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Equine Rhinopneumonitis Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Equine Rhinopneumonitis Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Equine Rhinopneumonitis Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Equine Rhinopneumonitis Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Equine Rhinopneumonitis Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Equine Rhinopneumonitis Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Equine Rhinopneumonitis Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Equine Rhinopneumonitis Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Equine Rhinopneumonitis Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Equine Rhinopneumonitis Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Equine Rhinopneumonitis Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Equine Rhinopneumonitis Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Equine Rhinopneumonitis Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Equine Rhinopneumonitis Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Equine Rhinopneumonitis Vaccine Sales Value Share by Country, 2025 VS 2032
7 Equine Rhinopneumonitis Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Equine Rhinopneumonitis Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Equine Rhinopneumonitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Equine Rhinopneumonitis Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Equine Rhinopneumonitis Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Equine Rhinopneumonitis Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Equine Rhinopneumonitis Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Equine Rhinopneumonitis Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Equine Rhinopneumonitis Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Equine Rhinopneumonitis Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Equine Rhinopneumonitis Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Equine Rhinopneumonitis Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Equine Rhinopneumonitis Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Equine Rhinopneumonitis Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Zoetis
  8. 8.2.1 Zoetis Company Information
  9. 8.2.2 Zoetis Business Overview
  10. 8.2.3 Zoetis Equine Rhinopneumonitis Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zoetis Equine Rhinopneumonitis Vaccine Product Portfolio
  12. 8.2.5 Zoetis Recent Developments
  13. 8.3 Santa Cruz Animal Health
  14. 8.3.1 Santa Cruz Animal Health Company Information
  15. 8.3.2 Santa Cruz Animal Health Business Overview
  16. 8.3.3 Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Product Portfolio
  18. 8.3.5 Santa Cruz Animal Health Recent Developments
  19. 8.4 Nisseiken Co., Ltd.
  20. 8.4.1 Nisseiken Co., Ltd. Company Information
  21. 8.4.2 Nisseiken Co., Ltd. Business Overview
  22. 8.4.3 Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Product Portfolio
  24. 8.4.5 Nisseiken Co., Ltd. Recent Developments
  25. 8.5 Boehringer Ingelheim
  26. 8.5.1 Boehringer Ingelheim Company Information
  27. 8.5.2 Boehringer Ingelheim Business Overview
  28. 8.5.3 Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Product Portfolio
  30. 8.5.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Equine Rhinopneumonitis Vaccine Value Chain Analysis
  2. 9.1.1 Equine Rhinopneumonitis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Equine Rhinopneumonitis Vaccine Sales Mode & Process
  6. 9.2 Equine Rhinopneumonitis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Equine Rhinopneumonitis Vaccine Distributors
  9. 9.2.3 Equine Rhinopneumonitis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst